Investigation Yields Potential New Genetic Biomarker for Anti–PD-1 Success in Melanoma

Source: AJMC, May 2022

Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.

Scientists appear to have identified a series of cancer-associated fibroblast (CAF) genes that with the potential to predict whether patients with melanoma will respond to anti–programmed cell death protein 1 (anti–PD-1) therapy.

The authors say the findings could one day help clinicians better manage existing patients and give drug developers potential new targets to improve the efficacy of anti–PD-1 therapy. Their findings were published in Frontiers in Medicine.

READ THE ORIGINAL FULL ARTICLE